Biomea Fusion (BMEA) Interest & Investment Income (2020 - 2026)
Biomea Fusion (BMEA) posted Interest & Investment Income of $430000.0 for Q1 2026, up 112.2% sequentially from -$3.5 million in Q4 2025, and down 4.44% YoY from $450000.0 in Q1 2025.
Biomea Fusion (BMEA) Interest & Investment Income (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Interest & Investment Income for 7 years, with the latest figure at $430000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 4.44% year-over-year to $430000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 55.13% YoY) and the FY2025 annual result came in at $1.9 million, down 67.08% from the prior year.
- Interest & Investment Income climbed to $430000.0 in Q1 2026 per BMEA's latest filing, from -$3.5 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $4.4 million in Q3 2025 and troughed at -$3.5 million in Q4 2025.
- A 5-year average of $1.1 million and a median of $962000.0 in 2022 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 3462.96% in 2022, then plunged 556.74% in 2025.
- Over 5 years, Interest & Investment Income stood at $962000.0 in 2022, then surged by 154.05% to $2.4 million in 2023, then tumbled by 68.41% to $772000.0 in 2024, then slumped by 556.74% to -$3.5 million in 2025, then surged by 112.2% to $430000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $430000.0, -$3.5 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 319,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 319,000.00 |
| Mar 31, 2026 | 430,000.00 |
| Dec 31, 2025 | -3.53 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 536,000.00 |
| Mar 31, 2025 | 450,000.00 |
| Dec 31, 2024 | 772,000.00 |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 2.44 Mn |
| Sep 30, 2023 | 2.69 Mn |
| Jun 30, 2023 | 2.77 Mn |
| Mar 31, 2023 | 980,000.00 |
| Dec 31, 2022 | 962,000.00 |
| Sep 30, 2022 | 594,000.00 |
| Jun 30, 2022 | 216,000.00 |
| Mar 31, 2022 | 34,000.00 |
| Dec 31, 2021 | 27,000.00 |
| Sep 30, 2021 | 32,000.00 |